Skip to main content
Premium Trial:

Request an Annual Quote

Genes2Me Signs European Distribution Deal With Axonlab

NEW YORK — Indian genetic testing company Genes2Me said on Tuesday that it has named Axonlab as a distribution partner in nine European markets.

Under the terms of the deal, Axonlab will offer Genes2Me's next-generation sequencing and point-of-care testing products in Switzerland, Liechtenstein, Austria, Germany, Slovenia, Croatia, Belgium, Luxembourg, and the Netherlands. Included in the arrangement are Genes2Me's sequencing-based assays for cancer, cardiovascular disease, and human leukocyte antigen typing, as well as its RapiQ-HT rapid point-of-care RT-PCR testing instrument.

Financial and other terms of the agreement were not disclosed.

Earlier this year, Genes2Me received CE marking for more than 25 next-generation sequencing-based panels for oncology, pharmacogenomics, and hereditary diseases. The firm also launched a COVID-19 testing kit about a year ago.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.